-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Cowen & Co. Downgrades Fate Therapeutics to Market Perform

Benzinga · 01/06/2023 06:06
Cowen & Co. analyst Tyler Van Buren downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Market Perform.